Two people can weigh the same and carry the same body fat percentage while facing very different health risks. The difference is usually where the fat sits, and the fat that matters most is the kind you cannot pinch.
Visceral vs. Subcutaneous Fat
Subcutaneous fat sits just under the skin. It is the fat you can grab, and metabolically it is relatively benign. Visceral fat wraps around the organs inside the abdominal cavity: liver, pancreas, intestines. It behaves like an active endocrine organ, releasing inflammatory cytokines and free fatty acids directly into portal circulation.
That is why visceral adiposity tracks so closely with insulin resistance, fatty liver disease, dyslipidemia, hypertension, and cardiovascular risk, often in people whose BMI looks unremarkable.
What Tesamorelin Does
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). Rather than introducing growth hormone directly, it prompts the pituitary to release your own GH in its natural pulsatile pattern, which is a meaningful distinction, because pulsatile release preserves normal feedback regulation.
Elevated GH and downstream IGF-1 increase lipolysis, and visceral adipose tissue is particularly rich in the receptors that respond. This is the mechanism behind tesamorelin's distinguishing characteristic: it reduces visceral fat preferentially, with comparatively little effect on subcutaneous fat.
What the Clinical Data Shows
Tesamorelin is FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy, and that trial program is the source of its strongest data. Reported findings across studies include:
- Roughly 15 to 20% reduction in visceral adipose tissue over 6 to 12 months
- Reduction in liver fat content in patients with hepatic steatosis
- Improved triglyceride profiles
- Preservation of lean body mass during fat reduction
- Regain of visceral fat after discontinuation without lifestyle change
That last point is the important one. It is a tool, not a cure. The underlying drivers of visceral accumulation still have to be addressed.
Where It Sits Alongside GLP-1 Therapies
GLP-1 and multi-agonist therapies reduce total body weight primarily by reducing intake. Tesamorelin does something different: it redistributes and mobilizes a specific fat depot while helping protect lean tissue. Clinically the two are sometimes discussed as complementary, one addressing overall energy balance, the other addressing the depot that carries the most metabolic risk.
Combining anything in this category requires real medical oversight. GH-axis therapies affect glucose handling, and stacking metabolic interventions without monitoring is how people get into trouble.
Lifestyle Levers That Move Visceral Fat
Visceral fat is actually among the more responsive tissues in the body. Before or alongside any therapy, these consistently work:
- Reduce liquid sugar and refined carbohydrate load: fructose in particular drives hepatic and visceral storage.
- Resistance training plus zone 2 cardio, the combination outperforms either alone for visceral reduction.
- Protect sleep, chronic short sleep raises cortisol and drives central fat deposition.
- Manage alcohol, one of the fastest routes to hepatic fat.
- Track waist circumference, not just weight: it is the simplest proxy for visceral change.
Testing Beats Guessing
Comprehensive lab panels and genomic markers reveal how efficiently you handle carbohydrates and fats, your inflammatory tendency, and your predisposition to central adiposity. That is the difference between following a generic plan and following yours.
This article is educational and is not medical advice or an offer to sell any product. Consult a licensed medical provider before beginning any therapy.